Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB

被引:45
作者
Benoit, V.
de Moraes, E.
Dar, N. A.
Taranchon, E.
Bours, V.
Hautefeuille, A.
Taniere, P.
Chariot, A.
Scoazec, J-Y
Gallo, C. V. de Moura
Merville, M-P
Hainaut, P.
机构
[1] Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France
[2] Univ Liege, Lab Med Chem & Human Genet, Ctr Biomed Integrated Genoproteom, Liege, Belgium
[3] Hop Edouard Herriot, Dept Pathol, Lyon, France
[4] State Uni Rio de Janeiro, Dept Cellular Biol & Genet, Rio De Janeiro, Brazil
关键词
p53; NF-kappaB; cyclooxygenase-2 esophageal cancer; Barrett's metaplasia;
D O I
10.1038/sj.onc.1209579
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Overexpression of cyclooxygenase-2 (Cox-2) is thought to exert antiapoptotic effects in cancer. Here we show that the tumor suppressor p53 upregulated Cox-2 in esophageal and colon cancer cell lines by inducing the binding of nuclear factor-kappaB (NF-kappaB) to its response element in the COX-2 promoter. Inhibition of NF-kappaB prevented p53 induction of Cox-2 expression. Cooperation between p53 and NF-kappaB was required for activation of COX-2 promoter in response to daunomycin, a DNA-damaging agent. Pharmacological inhibition of Cox-2 enhanced apoptosis in response to daunomycin, in particular in cells containing active p53. In esophageal cancer, there was a correlation between Cox-2 expression and wild-type TP53 in Barrett's esophagus (BE) and in adenocarcinoma, but not in squamous cell carcinoma (P < 0.01). These results suggest that p53 and NF-kappaB cooperate in upregulating Cox-2 expression, promoting cell survival in inflammatory precursor lesions such as BE.
引用
收藏
页码:5708 / 5718
页数:11
相关论文
共 57 条
  • [1] Barnas C, 1997, INT J CANCER, V71, P79, DOI 10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO
  • [2] 2-4
  • [3] Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis
    Beltrami, E
    Plescia, J
    Wilkinson, JC
    Duckett, CS
    Altieri, DC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (03) : 2077 - 2084
  • [4] Additive effect between NF-κB subunits and p53 protein for transcriptional activation of human p53 promoter
    Benoit, V
    Hellin, AC
    Huygen, S
    Gielen, J
    Bours, V
    Merville, MP
    [J]. ONCOGENE, 2000, 19 (41) : 4787 - 4794
  • [5] Bentires-Alj M, 1999, CANCER RES, V59, P811
  • [6] Inhibition of the NF-κB transcription factor increases Bax expression in cancer cell lines
    Bentires-Alj, M
    Dejardin, E
    Viatour, P
    Van Lint, C
    Froesch, B
    Reed, JC
    Merville, MP
    Bours, V
    [J]. ONCOGENE, 2001, 20 (22) : 2805 - 2813
  • [7] NF-κB and chemoresistance:: could NF-κB be an antitumor target?
    Bentires-Alj, M
    Merville, MP
    Bours, V
    [J]. DRUG RESISTANCE UPDATES, 1999, 2 (04) : 274 - 276
  • [8] Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid
    Birkenkamp-Demtroder, K
    Olesen, SH
    Sorensen, FB
    Laurberg, S
    Laiho, P
    Aaltonen, LA
    Orntoft, TF
    [J]. GUT, 2005, 54 (03) : 374 - 384
  • [9] p53 induces NF-κB activation by an IκB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1
    Bohuslav, J
    Chen, LF
    Kwon, H
    Mu, YJ
    Greene, WC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (25) : 26115 - 26125
  • [10] Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus
    Buskens, CJ
    Sivula, A
    van Rees, BP
    Haglund, C
    Offerhaus, GJA
    van Lanschot, JJB
    Ristimäki, A
    [J]. GUT, 2003, 52 (12) : 1678 - 1683